Format

Send to

Choose Destination
See comment in PubMed Commons below
Acta Neurol Scand. 2007 May;115(5):347-50.

Pregabalin in restless legs syndrome with and without neuropathic pain.

Author information

1
Department of Clinical Neurophysiology, University of Goettingen, Goettingen, Germany. msommer@med.uni-goettingen.de

Abstract

BACKGROUND:

Restless legs syndrome (RLS) is a common neurological disorder complicated in many patients by augmentation to dopaminergic therapy or comorbidities such as neuropathic pain.

AIMS:

To explore the effectiveness of pregabalin in RLS in a pragmatic clinical setting.

METHODS:

After observing improvement of restless legs symptoms in seven patients treated with pregabalin for neuropathic pain, we extended the clinical observation to a total of 16 patients with secondary RLS, in most of them due to neuropathy, and to three patients with idiopathic RLS.

RESULTS:

Three patients discontinued pregabalin because of side effects (rash, fatigue, loss of efficacy). The other 16 patients self-rated a satisfactory or good alleviation of RLS symptoms and maintained pregabalin, five with add-on medication, on a mean daily dose of 305 mg (standard deviation, 185 mg), and with a mean duration of 217 (standard deviation, 183) days.

CONCLUSION:

These data propose pregabalin as a new option in the treatment of secondary RLS for patients with neuropathic pain, which should be further investigated with randomized, placebo-controlled trials.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center